BioLine RxBLRX -0.16%23 Pretax Margin % is -542.56% as of Mar. 2026. GuruFocus rates BLRX with a GF Score™ of 23/100. The stock has 5 warning signs investors should review. Among 944 Biotechnology companies, BioLine Rx ranks worse than 74.58% on this metric.
Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. BioLine Rx's Pre-Tax Income for the
three
months ended in Mar. 2026 was $-2.59 Mil. BioLine Rx's Revenue for the
three
months ended in Mar. 2026 was $0.48 Mil. Therefore, BioLine Rx's pretax margin for the quarter that ended in Mar. 2026 was -542.56%.
The historical rank and industry rank for BioLine Rx's Pretax Margin % or its related term are showing as below:
BLRX'
s Pretax Margin % Range Over the Past 10 Years
Min: -1262.77 Med: -171.69 Max: -31.86
Current: -694.66
BLRX's Pretax Margin % is ranked worse than 74.58% of 944
companies
in the Biotechnology industry
Industry Median: -90.5
vs BLRX: -694.66
BioLine Rx (NAS:BLRX) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
BioLine Rx Pretax Margin % Related Terms
BioLine Rx Pretax Margin % Historical Data
* Premium members only.
The historical data trend for BioLine Rx's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BLRX vs VRTX, REGN, ALNY: Pretax Margin % Comparison
For the Biotechnology subindustry, BioLine Rx's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioLine Rx Pretax Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, BioLine Rx's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where BioLine Rx's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioLine Rx (BLRX) has a Pretax Margin % of -542.56% as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioLine Rx and its competitors. According to the industry distribution chart, BioLine Rx ranks #704 out of 944 companies in the Biotechnology industry, placing it in the top 74.6%.
Is BioLine Rx's Pretax Margin % too high?
BioLine Rx's current Pretax Margin % is -542.56%. Based on the distribution chart, BioLine Rx ranks #704 out of 944 companies in the Biotechnology industry, which is below the industry midpoint. Overall, BioLine Rx has a GF Score™ of 23/100, reflecting its overall financial health beyond just this single metric.
How does BioLine Rx's Pretax Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, BioLine Rx ranks #704 out of 944 companies for Pretax Margin %. This places BioLine Rx in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Biotechnology company?
A good Pretax Margin % depends on the Biotechnology industry context. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on BioLine Rx and its competitors. BioLine Rx's current Pretax Margin % is -542.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioLine Rx stock overvalued right now?
BioLine Rx (BLRX) has a current Pretax Margin % of -542.56%. The current Pretax Margin % is -542.56%. BioLine Rx's overall GF Score™ is 23/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For BioLine Rx (BLRX), the current Pretax Margin % is -542.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
23GF Score
Get the complete analysis for BLRX
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BLRX has been successfully added to your 
